These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 16185567)
21. Infliximab in inflammatory bowel disease: attention to adverse events. Uyanikoglu A; Ermis F; Akyuz F; Pinarbasi B; Baran B; Aydogan T; Demir K; Besisik F; Kaymakoglu S Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2337-42. PubMed ID: 25219835 [TBL] [Abstract][Full Text] [Related]
22. Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Rutgeerts P; Van Assche G; Vermeire S Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465 [TBL] [Abstract][Full Text] [Related]
23. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. Gustavsson A; Järnerot G; Hertervig E; Friis-Liby I; Blomquist L; Karlén P; Grännö C; Vilien M; Ström M; Verbaan H; Hellström PM; Magnuson A; Halfvarson J; Tysk C Aliment Pharmacol Ther; 2010 Oct; 32(8):984-9. PubMed ID: 20937043 [TBL] [Abstract][Full Text] [Related]
24. Tuberculosis and treatment with infliximab. Zhang Z; Correa H; Bégué RE N Engl J Med; 2002 Feb; 346(8):623-6. PubMed ID: 11859880 [No Abstract] [Full Text] [Related]
25. Severe rosacea in a patient on infliximab for ulcerative colitis: pathophysiological considerations. Kosmidou M; Gaitanis G; Nomikos K; Zioga A; Katsanos K; Bassukas ID; Tsianos E Acta Derm Venereol; 2009; 89(5):522-3. PubMed ID: 19734983 [No Abstract] [Full Text] [Related]
26. Golimumab for moderately to severely active ulcerative colitis. Kedia S; Ahuja V; Makharia GK Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886 [TBL] [Abstract][Full Text] [Related]
27. Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn's disease. Izbéki F; Nagy F; Szepes Z; Kiss I; Lonovics J; Molnár T Inflamm Bowel Dis; 2008 Mar; 14(3):429-31. PubMed ID: 17973302 [No Abstract] [Full Text] [Related]
28. Attention to Infliximab adverse events: chimeric monoclonal antibodies can induce anti chimeric antibodies that may result in Kounis hypersensitivity associated acute coronary syndrome. Kounis NG; Kounis GN; Soufras GD; Tsigkas G; Hahalis G Eur Rev Med Pharmacol Sci; 2014; 18(24):3735-6. PubMed ID: 25555859 [No Abstract] [Full Text] [Related]
29. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533 [TBL] [Abstract][Full Text] [Related]
30. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy. Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791 [TBL] [Abstract][Full Text] [Related]
31. Nephrotic syndrome after infliximab treatment in a patient with ulcerative colitis. Dumitrescu G; Dahan K; Treton X; Corcos O; Bouhnik Y; Stefanescu C J Gastrointestin Liver Dis; 2015 Jun; 24(2):249-51. PubMed ID: 26114187 [TBL] [Abstract][Full Text] [Related]
32. Listeria meningitis complicating a patient with ulcerative colitis on concomitant infliximab and hydrocortisone. Parihar V; Maguire S; Shahin A; Ahmed Z; O'Sullivan M; Kennedy M; Smyth C; Farrell R Ir J Med Sci; 2016 Nov; 185(4):965-967. PubMed ID: 26358724 [TBL] [Abstract][Full Text] [Related]
34. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis. Zhou Z; Dai C; Liu WX Hepatogastroenterology; 2015; 62(138):309-18. PubMed ID: 25916055 [TBL] [Abstract][Full Text] [Related]
35. Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. Angelucci E; Cocco A; Viscido A; Vernia P; Caprilli R Inflamm Bowel Dis; 2007 Aug; 13(8):1059-61. PubMed ID: 17387676 [No Abstract] [Full Text] [Related]